Drugs.com, an online clinical drug resource, and TrialReachare partnering to provide patients with information and access to treatments that are still under development. The new partnership will bring TrialReach's patient-centric content and tools directly to the 25 million people who visit Drugs.com every month.

From a patient's perspective, clinical trials offer more treatment options when the standard ones fail. They also give patients the opportunity to participate in medical research that may also help other patients in the future.

"There are millions of patients searching for information about medicines on Drugs.com. Giving them the ability to find information about new drugs in development is a natural extension of how people are using the site today," said Pablo Graiver, TrialReach CEO. "But we want to go beyond this. Our partnership gives us the opportunity to give many more patients the ability to voice their needs and experiences so researchers can design better treatments and trials in the future."

"As the Internet's largest provider of information about medicines, it only makes sense that we would give our community information about the latest drugs in development and give them an opportunity to participate in clinical trials," says Philip Thornton, CEO of Drugs.com. We chose TrialReach to partner with because they are delivering a much better experience for patients through technology and insight."

The intersection of technology, data science and social media is creating unparalleled opportunities to gather information and insights about drug development and testing from understanding how and where trials should be conducted to how clinical trials can be made more accessible and less burdensome to patients.

"Everyone is talking about big data but we have to go beyond data to actionable insights so we can deliver something meaningful to patients," said Graiver. "What do patients care about? What are they experiencing?  We think that by allowing people to 'voice' their knowledge and their experience of clinical trials either directly on our site or through social media, we can make clinical trial information more up-to-date, more relevant and more valuable to patients and researchers than ever before."